EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Thrombospondin-2 in Cardiovascular Disease: Molecular Mechanisms, Biomarker Potential, and Therapeutic Perspectives

Karolina L Stępień iD, Malwina Botor, Jakub Karliński iD, Alicja Kazik iD, Grzegorz Machnik iD

Cells · 26.06.2026 · 15 (13) · 1162

DOI: 10.3390/cells15131162 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.06.2026. Verfasst von Karolina L Stępień und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752 Katowice, Poland. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Thrombospondins, Biomarkers. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional, Medical University of Silesia in Katowice, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombospondin-2 (TSP-2) is an extracellular matrix glycoprotein involved in angiogenesis, vascular remodeling, cell adhesion, and tissue repair. Its expression is induced by pathological stimuli, including mechanotransduction, hypoxia, and TGF-β signaling, and has been associated with several cardiovascular diseases (CVDs), such as heart failure, coronary artery disease, abdominal aortic aneurysm, and hypertension. Elevated circulating TSP-2 levels, particularly in combination with NT-proBNP, as well as alterations in THBS2 and its regulatory non-coding RNAs, have been linked to disease severity and adverse cardiovascular outcomes. This review summarizes current evidence on the role of TSP-2 in cardiovascular pathophysiology and its involvement in cardiovascular homeostasis. Although accumulating data suggest that TSP-2 may have diagnostic, prognostic, and therapeutic relevance, its clinical utility as a biomarker or therapeutic target has not yet been established. Further large-scale studies and standardized assessment methods are required to validate its potential and support future clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesThrombospondinsBiomarkersHumansThrombospondin 2Animals

Stichwörter der Autor:innen

biomarkercardiovascular diseasesextracellular matrixthrombospondin-2

Substanzen

Thrombospondin 2ThrombospondinsBiomarkers

Autor:innen und Institutionen

  • Department of Molecular Biology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medykow 18 Street, 40-752 Katowice, Poland.
  • Students' Scientific Society, Department of Molecular Biology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.

ORCID-Profile: Karolina L Stępień, Jakub Karliński, Alicja Kazik, Grzegorz Machnik

Förderung

  • Institutional
  • Medical University of Silesia in Katowice, Poland

Zitieren

APA

Stępień, K. L., Botor, M., Karliński, J., Kazik, A., & Machnik, G. (2026). Thrombospondin-2 in Cardiovascular Disease: Molecular Mechanisms, Biomarker Potential, and Therapeutic Perspectives. Cells, 15(13), 1162. https://doi.org/10.3390/cells15131162

Vancouver

Stępień KL, Botor M, Karliński J, Kazik A, Machnik G. Thrombospondin-2 in Cardiovascular Disease: Molecular Mechanisms, Biomarker Potential, and Therapeutic Perspectives. Cells. 2026;15(13):1162. doi:10.3390/cells15131162

BibTeX
@article{Stpie2026,
  author = {Stępień, Karolina L and Botor, Malwina and Karliński, Jakub and Kazik, Alicja and Machnik, Grzegorz},
  title = {Thrombospondin-2 in Cardiovascular Disease: Molecular Mechanisms, Biomarker Potential, and Therapeutic Perspectives},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {1162},
  doi = {10.3390/cells15131162}
}
Kostenlos starten →